177 related articles for article (PubMed ID: 30507300)
21. Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1.
Zhao J; Shi L; Zeng S; Ma C; Xu W; Zhang Z; Liu Q; Zhang P; Sun Y; Xu C
Urol Oncol; 2018 Jun; 36(6):311.e1-311.e13. PubMed ID: 29602637
[TBL] [Abstract][Full Text] [Related]
22. Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach.
Alberice JV; Amaral AF; Armitage EG; Lorente JA; Algaba F; Carrilho E; Márquez M; García A; Malats N; Barbas C
J Chromatogr A; 2013 Nov; 1318():163-70. PubMed ID: 24139504
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemistry Biomarkers in Nonmuscle Invasive Bladder Cancer.
Ranzi AD; da Silva JN; Graziottin TM; Annels N; Bica CG
Appl Immunohistochem Mol Morphol; 2017 Mar; 25(3):178-183. PubMed ID: 26574637
[TBL] [Abstract][Full Text] [Related]
24. Metabonomic profiling of bladder cancer.
Chan EC; Pasikanti KK; Hong Y; Ho PC; Mahendran R; Raman Nee Mani L; Chiong E; Esuvaranathan K
J Proteome Res; 2015 Feb; 14(2):587-602. PubMed ID: 25388527
[TBL] [Abstract][Full Text] [Related]
25. Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer.
Latosinska A; Frantzi M; Vlahou A; Mischak H
Proteomics Clin Appl; 2013 Dec; 7(11-12):779-93. PubMed ID: 23970371
[TBL] [Abstract][Full Text] [Related]
26. Capillary electrophoresis-mass spectrometry for targeted and untargeted analysis of the sub-5 kDa urine metabolome of patients with prostate or bladder cancer: A feasibility study.
MacLennan MS; Kok MGM; Soliman L; So A; Hurtado-Coll A; Chen DDY
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Feb; 1074-1075():79-85. PubMed ID: 29334632
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of statistical techniques to normalize mass spectrometry-based urinary metabolomics data.
Cook T; Ma Y; Gamagedara S
J Pharm Biomed Anal; 2020 Jan; 177():112854. PubMed ID: 31518861
[TBL] [Abstract][Full Text] [Related]
28. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
[TBL] [Abstract][Full Text] [Related]
29. Detection of survivin expression in bladder cancer and renal cell carcinoma using specific monoclonal antibodies.
Chen D; Xu J; Zhang Q
Oncol Rep; 2018 Jun; 39(6):2817-2828. PubMed ID: 29658613
[TBL] [Abstract][Full Text] [Related]
30. SWATHtoMRM: Development of High-Coverage Targeted Metabolomics Method Using SWATH Technology for Biomarker Discovery.
Zha H; Cai Y; Yin Y; Wang Z; Li K; Zhu ZJ
Anal Chem; 2018 Mar; 90(6):4062-4070. PubMed ID: 29485856
[TBL] [Abstract][Full Text] [Related]
31. Biotransformation-based metabolomics profiling method for determining and quantitating cancer-related metabolites.
Yue X; He J; Zhang R; Xu J; Zhou Z; Zhang R; Bi N; Wang Z; Sun C; Wang L; Chen Y; Abliz Z
J Chromatogr A; 2018 Dec; 1580():80-89. PubMed ID: 30473010
[TBL] [Abstract][Full Text] [Related]
32. Urinary APE1/Ref-1: A Potential Bladder Cancer Biomarker.
Choi S; Shin JH; Lee YR; Joo HK; Song KH; Na YG; Chang SJ; Lim JS; Jeon BH
Dis Markers; 2016; 2016():7276502. PubMed ID: 27057081
[TBL] [Abstract][Full Text] [Related]
33. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
[TBL] [Abstract][Full Text] [Related]
34. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
35. Increased expression of immediate early response gene 3 protein promotes aggressive progression and predicts poor prognosis in human bladder cancer.
Ye J; Zhang Y; Cai Z; Jiang M; Li B; Chen G; Zeng Y; Liang Y; Wu S; Wang Z; He H; Zhong W; Wu CL
BMC Urol; 2018 Sep; 18(1):82. PubMed ID: 30249226
[TBL] [Abstract][Full Text] [Related]
36. Recent and potential developments of biofluid analyses in metabolomics.
Zhang A; Sun H; Wang P; Han Y; Wang X
J Proteomics; 2012 Feb; 75(4):1079-88. PubMed ID: 22079244
[TBL] [Abstract][Full Text] [Related]
37. Targeted metabolomics in bladder cancer: From analytical methods development and validation towards application to clinical samples.
Yumba Mpanga A; Siluk D; Jacyna J; Szerkus O; Wawrzyniak R; Markuszewski M; Matuszewski M; Kaliszan R; Markuszewski MJ
Anal Chim Acta; 2018 Dec; 1037():188-199. PubMed ID: 30292293
[TBL] [Abstract][Full Text] [Related]
38. Low Expression of Toll-like Receptor 4 Is Associated With Poor Prognosis in Bladder Cancer.
Kusuhara Y; Daizumoto K; Kawai K; Hirayama K; Kowada M; Shintani T; Fukuhara Y; Dondoo TO; Ozaki K; Tsuda M; Fukawa T; Nakatsuji H; Bando Y; Uehara H; Fukumori T; Takahashi M; Kanayama HO
Anticancer Res; 2019 Feb; 39(2):703-711. PubMed ID: 30711948
[TBL] [Abstract][Full Text] [Related]
39. SOX2 Is a Marker for Stem-like Tumor Cells in Bladder Cancer.
Zhu F; Qian W; Zhang H; Liang Y; Wu M; Zhang Y; Zhang X; Gao Q; Li Y
Stem Cell Reports; 2017 Aug; 9(2):429-437. PubMed ID: 28793245
[TBL] [Abstract][Full Text] [Related]
40. Decreased TRPM7 inhibits activities and induces apoptosis of bladder cancer cells via ERK1/2 pathway.
Cao R; Meng Z; Liu T; Wang G; Qian G; Cao T; Guan X; Dan H; Xiao Y; Wang X
Oncotarget; 2016 Nov; 7(45):72941-72960. PubMed ID: 27662662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
